Bath & Body Works (BBWI) closed Friday at $26.14, down 31% from its twelve-month high, while GitLab (GTLB) trades at $47.82, off 28% from peak. Both names now appear on sponsor screens alongside two undisclosed mid-cap candidates, each carrying enterprise values between $3.2B and $7.8B. The VIX printed 22.7 on Friday, elevated but not panicked—the kind of backdrop that opens negotiation rooms without forcing rushed bids.

The five-box template matters because it narrows 2,400 publicly traded U.S. equities to fewer than 40 viable candidates in any given quarter. Box one: predictable cash flow, meaning three consecutive years of positive operating cash with less than 15% variance quarter-to-quarter. Box two: depressed valuation, defined here as trading below 0.85x the sector median EV/EBITDA multiple. Box three: management continuity—no CEO turnover in the prior 18 months. Box four: a defensible market position, typically 18% category share or higher in a fragmented vertical. Box five: clean capital structure with less than 2.5x net debt to EBITDA, leaving room for the 5x-6x leverage sponsors layer in.

Bath & Body Works fits because its $6.1B enterprise value sits 22% below the specialty retail median on an EV/EBITDA basis, while trailing twelve-month operating cash flow ran $891M with 9% variance across quarters. The company holds 34% share in U.S. fragrance bath products, a category that grew 4.1% annually through the past cycle. GitLab's case rests on $1.2B in deferred revenue—contracted but not yet recognized—and gross margins above 88%, the kind of software economics that survive interest-rate stress. Its $7.2B enterprise value trades at 6.8x forward revenue, down from 11.2x eighteen months ago when zero-rate capital still flowed freely.

The two unnamed candidates matter more than the named ones. Sponsors rarely announce targets before term sheets clear, and the appearance of a public list suggests the screening work finished weeks ago. One likely sits in business services with recurring revenue north of 70%. The other probably carries industrial exposure—something in logistics software or vertical SaaS serving manufacturing—where tariff concerns and supply-chain rewiring create valuation dislocations but don't break the underlying cash generation. These profiles tend to close at 9x-11x EBITDA in the current environment, down from 12x-14x pre-correction.

Allocators should track three follow-on events. First, any 13D filings on these four names in the next 30-45 days, particularly from Vista, Thoma Bravo, or the Carlyle software group. Second, credit-agreement amendments that create change-of-control carve-outs, a technical step that precedes formal processes. Third, the appearance of boutique M&A advisors—Qatalyst, Evercore, Centerview—in quarterly earnings acknowledgments, the polite way companies signal they've retained sell-side counsel without filing an 8-K.

The VIX at 22.7 won't last. Either it climbs past 28 and deals pause, or it falls below 18 and the entry discount narrows. Sponsors with $187B in committed-but-undeployed software and consumer capital know the math: a 26% valuation haircut today funds the same equity check that required 19% less cash eighteen months ago.